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Gene expression proﬁling of PPARα has been used in several studies, but fewer studies went further to identify the tissue-speciﬁc
pathways or genes involved in PPARα activation in genome-wide. Here, we employed and applied gene set enrichment analysis to
twomicroarraydatasetsbothPPARαrelated respectively inmouseliverandintestine.We suggestedthattheregulatorymechanism
of PPARα activation by WY14643 in mouse small intestine is more complicated than in liver due to more involved pathways.
Several pathways were cancer-related such as pancreatic cancer and small cell lung cancer, which indicated that PPARα may have
an important role in prevention of cancer development. 12 PPARα dependent pathways and 4 PPARα independent pathways were
identiﬁedhighlycommoninbothliverandintestineofmice.Mostofthemweremetabolismrelated,suchasfattyacidmetabolism,
tryptophan metabolism, pyruvate metabolism with regard to PPARα regulation but gluconeogenesis and propanoate metabolism
independent of PPARα regulation. Keratan sulfate biosynthesis, the pathway of regulation of actin cytoskeleton, the pathways
associated with prostate cancer and small cell lung cancer were not identiﬁed as hepatic PPARα independent but as WY14643
dependent ones in intestinal study. We also provided some novel hepatic tissue-speciﬁc marker genes.
1.Introduction
Peroxisome proliferator-activated receptor α (PPARα)i sa
ligand-activated transcription factor which is one of mem-
bers of the nuclear-hormone receptor (NR) superfamily [1–
3]. WY14643 is one of synthetic ligands, which is primarily
an activator of PPARα [4, 5]. In mammals, high levels of
PPARα expression are found in tissues with active fatty acid
catabolism, such as liver heart, kidney, brown adipose tissue,
muscle, small intestine, and the large intestine [1, 2, 6]. The
liver is a central player in the whole body energy homeostasis
byitsabilitytoorchestratefattyacidandglucosemetabolism,
and it plays an important role in fatty acid oxidation
regulated by PPARα [7]. During the past 15 years, numerous
studies with PPARα null mice have demonstrated the critical
roles played by this receptor in energy metabolism, hepatic
steatosis, inﬂammation, cardiac pathophysiology, cell-cycle
alterations, and hepatocarcinogenesis [8, 9]. In recent years,
microarray technology has been highly used to map PPARα-
dependent genes and further characterizes PPARα function
in diﬀerent tissues in genome wide [10–15]. However, most
of gene expression proﬁlings of PPARα has been almost
exclusively studied in liver. In liver study, PPARα is shown
to be critical for the coordinate transcriptional activation
of genes involved in lipid catabolism, including cellular
fatty acid uptake and activation, mitochondrial β-oxidation,
peroxisomal fatty acid oxidation,
ketone body synthesis, fatty acid elongation and desatu-
ration, and apolipoprotein synthesis [16, 17].
In addition, several studies on the functions of PPARα
and PPARα target genes in mouse nonhepatic tissues (such
as small intestine) had also been done [12, 14, 18]. For
example, a genome-wide microarray method was performed
to examine the eﬀects of PPARα agonists on the expression
levels of all the nutrient/drug plasma-membrane trans-
porters in the mouse small intestine as a result, which show2 PPAR Research
expression levels of seven nutrient/drug transporters such as
Abcd3 and Octn2 in the intestine were upregulated and the
expression level of one (Mrp1/Abcc1) was downregulated by
PPARα [12]. Actually, we could suppose that the regulatory
mechanisms of PPARα in mouse tissues are diverse in some
cases. Therefore, a comparative study using the same analysis
method on genome wide expression datasets between in
hepatic and in nonhepatic tissue of mice is essential for us to
identify tissue-speciﬁc pathways or genes involved in PPARα
activation. It may be helpful for us to get comprehensive
knowledge on the biological functions of PPARα in distinct
tissues of mice. Moreover, in order to evaluate PPAR-
dependent and independent eﬀects on tissue-speciﬁc gene
expression, a null mutation in the PPAR gene was generally
used, similarly, with the treatment of WY14643 or not
was usually employed to deﬁne the role of WY14643 in
PPAR activation [13, 19, 20]. Thus, identiﬁcation of PPAR-
dependent or independent pathways and WY14643 PPAR-
dependent or independent pathways by comparison of gene
expression proﬁles in diﬀerent tissues may provide insight
into the PPAR-mediated homeostasis.
Here, we employed two published microarray datasets
both PPARα related, respectively, in mouse liver and intes-
tine, and applied GSEA to them in order to compare
the regulatory mechanisms of gene expression by PPARα
activation between in small intestine and in liver of mice
and indentify PPARα-dependent or independent pathways
under WY14643 treatment or not. Concretely, PPARα-
dependent pathways would be identiﬁed by comparing
PPARα knockout (KO) to wild type (WT) animals alone,
while WY14643 PPARα-dependent pathways would be iden-
tiﬁed by comparing KO to WT treated with WY14643;
WY14643-dependent pathways would be identiﬁed by com-
paring with the treatment of WY14643 or not in WT animal,
while PPARα-independent pathways would be identiﬁed by
comparing with the treatment of WY14643 or not in KO
animal.
2.MaterialsandMethods
2.1. Microarray Datasets Collection and Preprocessing. We
searched GEO (http://www.ncbi.nlm.nih.gov/geo/) for the
gene expression proﬁling studies related to PPARα knockout.
Datawereincludedinourreanalysisiftheymetthefollowing
conditions: (1) the data is in genome-wide, (2) comparison
was conducted between PPARα knockout and wild type, and
(3) complete microarray raw or normalized data are avail-
able. Finally, we chose the datasets GSE5475 and GSE8295
for our reanalysis studies, which were both contributed
by Guido Hooiveld in diﬀerent periods, respectively, for
mouse small intestine and liver [14, 15]. The summary
of these two datasets was shown in Table 1. In those two
datasets, pure bred wild type (129S1/SvImJ) and PPARα-
null (129S4/SvJae) mice were both treated with the synthetic
PPARα ligand WY14643 (0.1% w/w) mixed in the food, or
normal food (control) for 5 days. In dataset GSE5475, the
complete intestines were then removed and total RNA was
isolated, RNA of 3 biological replicates was hybridized to
Aﬀymetrix 430A arrays. In dataset GSE8295, liver total RNA
Table 1: Summary of re-analyzed datasets.
Dataset Period Platform Probes Tissue No. of
samples
GSE5475 Aug, 2006 MOE430A 22k Intestine 12
GSE8295 Jun, 2007 Mouse430 2 45k Liver 16
There were two datasets named GSE5475 and GSE8295 for our reanalysis
studies, which were both contributed by Guido Hooiveld in diﬀerent
periods (August in 2006 and June in 2007), respectively, for mouse small
intestineandliver.TheplatformsusedherewereAﬀymetrix430Aarraysand
Aﬀymetrix mouse genome 430 2.0 GeneChip arrays. The sample sizes were
12 and 16 respectively.
from 4 biological replicates was hybridized onto Aﬀymetrix
mouse genome 430 2.0 GeneChip arrays. The details of the
information about our divided eight studies from these two
datasets can be seen in Table 2. On the one hand, we were
focused on studying the eﬀects of PPARα-dependent side.
Among them, there were four studies. Study 1: Intestine-
CT (KO/WT) is the study of mouse small intestine of wild
type versus PPARα-null mice treated with normal food in
GSE5475; Study 2: Intestine-WY (KO/WT) is the study of
mouse small intestine of wild type versus PPARα-null mice
treated with PPARα agonist WY14643 for 5 days also in
GSE5475; Study 3: Liver-CT (KO/WT) is the study of mouse
l i v e ro fw i l dt y p ev e r s u sP P A R α-null mice treated with
normal food in GSE8295; Study 4: Liver-WY (KO/WT) is
the study of mouse liver of wild type versus PPARα-null
mice treated with the PPARα agonist WY14643 for 5 days
also in GSE8295. On the other hand, additional 4 studies
were followed to assess the eﬀects of PPARα-independent
side. Study 5: Intestine-WT (CT/WY) is the study of wild
type mice intestine with or without WY14643 treatment
in GSE5475; Study 6: Intestine-KO (CT/WY) is the study
of PPARα-null mice intestine with or without WY14643
treatment in GSE5475; Study 7: Liver-WT (CT/WY) is the
study of wild type mice liver with or without WY14643
treatment in GSE8295; Study 8: Liver-KO (CT/WY) is the
study of PPARα-null mice liver with or without WY14643
treatment in GSE8295. According to the eight comparisons
above,wecouldidentifydependentorindependentpathways
for PPARα or WY14643. From study 1 and 3, we could
get PPARα-dependent pathway; from 2 and 4, we could
get WY14643 PPARα-dependent pathways; from study 5
and 7, WY14643-dependent pathways could be identiﬁed;
from study 6 and 8, PPARα-independent pathways could be
identiﬁed.
For the assessment of the inﬂuence of preprocessing on
the comparison, the data preprocessing was performed using
software packages developed in version 2.6.0 of Biocon-
ductor and R version 2.10.1 [25]. Each Aﬀymetrix dataset
was background adjusted, normalized and log2 probe-set
intensities calculated using the robust multichip averaging
(RMA) algorithm in Aﬀyp a c k a g e[ 26].
Nowadays, the analysis of genomic data has become an
important challenge in bioinformatics. Currently, the most
well-known method named gene set enrichment Analysis
(GSEA) has been widely used to analyze gene expression
proﬁles, especially to identify predeﬁned gene sets whichPPAR Research 3
Table 2: Summary of 8 comparison studies.
Study Comparison name Identiﬁed pathways
1 Intestine-CT (KO/WT) PPARα-dependent pathway in intestine
3 Liver-CT (KO/WT) PPARα-dependent pathway in liver
2 Intestine-WY (KO/WT) WY14643 PPARα-dependent pathways in
intestine
4 Liver-WY (KO/WT) WY14643 PPARα-dependent pathways in liver
5 Intestine-WT (CT/WY) WY14643-dependent pathways in intestine
7 Liver-WT (CT/WY) WY14643-dependent pathways in liver
6 Intestine-KO (CT/WY) PPARα-independent pathways in intestine
8 Liver-KO (CT/WY) PPARα-independent pathways in liver
There were 8 comparison studies related to PPARα in mice intestine or in liver included in our research. Each of the 8 comparisons identiﬁed dependent or
independent pathways for PPARα or WY14643.
CT: mice were treated with normal food (control).
WY: mice were treated with the synthetic PPARα ligand WY14643 (0.1% w/w) mixed in the food.
KO: PPARα-null (129S4/SvJae) mice.
WT: wild type (129S1/SvImJ) mice.
exhibited signiﬁcant diﬀerences in expression between sam-
ples from control and treated [21, 22]. The algorithms
calculate the statistical signiﬁcance of the expression changes
across groups or pathways rather than individual gene,
thus allowing identiﬁcation of groups or pathways most
strongly aﬀected by the observed expression changes. The
a n a l y s i sb a s e do nag r o u po fr e l e v a n tg e n e si n s t e a do fo n
an individual gene increases the likelihood for investigators
to identify the critical functional processes under the bio-
l o g i c a lp h e n o m e n ai ne a c hs t u d y .T h eg o a lo fG S E Ai st o
determine other interesting categories (pathways), where the
constituent genes show coordinated changes in expression
over the experimental conditions, other than in the form
of sets of diﬀerentially expressed genes. Compared to other
methods, one of the advantages of GSEA is the relative
robustness to noise and outliers in the data, especially for
considering the comparison of two diﬀerent groups, or
phenotypes. In other words, it is able to highlight genes
weaklyconnectedtothephenotypethroughpathwayanalysis
which may be diﬃcult to detect by using classical univariate
statistics. Moreover, GSEA is likely to be more powerful than
conventional single-gene methods in the study of complex
diseases in which many genes make subtle contributions. For
example, a previous research study has successfully applied
GSEA to evaluate the psoriasis transcriptome across diﬀer-
ent studies, overcoming the shortcomings of overlapping
individual diﬀerentially expressed genes (DEG) approach
[23]. In order to further investigate the pathogenesis of
endometriosis, our group have also performed a cross-
study GSEA in endometriosis. As a result, we increased
the concordance to identify many biological mechanisms
involved in endometriosis, which are novel in terms of their
connection to endometriosis [24].
2.2. Gene Set Enrichment Analysis. Here, we performed our
gene set enrichment analysis on each study above to identify
signiﬁcantly related pathways and genes to either PPARα
or WY14643-dependent or independent eﬀects by using
Category package in version 2.6.0 of Bioconductor [27].
In our research, the gene sets represented by less than
10 genes were excluded. The t-statistic mean of the genes
was computed in each pathway. Using a permutation test
with 1000 times, the signiﬁcantly changed pathways were
identiﬁed with P value ≤ 0.01. Accordingly, the signiﬁcant
pathways and genes between PPARα knockout and wild type
were then identiﬁed in either control or WY14643 (0.1%
w/w) condition. Subsequently, the comparison of GSEA
results based on the datasets between in small intestine and
in liver of mice was performed to indicate the regulatory
mechanisms of gene expression by PPARα activation of each
other.
3. Results and Discussion
Here, we used standardized microarray preprocessing and
GSEA with comprehensive expression proﬁles in order to
ﬁnd greater data convergence and provide a systematic
insight into the pathways altered between mouse hepatic
and intestinal expression under the treatment of PPARα
knockout and WY14643 mixed diet or not.
3.1. Pathway Analysis of PPARα-dependent Gene Regulation.
Firstly, the common GSEA method was applied to the ﬁrst 4
studies of PPARα-dependent side. For individual analysis, we
obtainedthesigniﬁcantpathwaysineachdataset,whichwere
summarized in Figure 1 and Additional File 1. The studies
of Intestine-CT (KO/WT) and Liver-CT (KO/WT) are
for identifying PPARα-dependent pathways by comparison
made between PPARα-null (KO) and wild type (WT) mice
without the treatment of WY14643; the studies of Intestine-
WY (KO/WT) and Liver-WY (KO/WT) are for identifying
WY14643 PPARα-dependent pathways by comparison made
between PPARα-null (KO) and wild type (WT) mice with
the treatment of WY14643, respectively, in small intestine
and liver. As a result, There were 35 and 25 in study of
Intestine-CT (KO/WT); 80 and 62 in study of Intestine-
WY (KO/WT); 45 and 29 in study of Liver-CT (KO/WT);
And 62 and 74 in study of Liver-WY (KO/WT), respectively,4 PPAR Research
Table 3: The highly common down and up regulated pathways identiﬁed in studies of PPARα-dependent or independent eﬀects both in
liver and small intestine tissues of mice.
Pathways PPARα-dependent (KO/WT) PPARα-independent (CT/WY)
Upregulated
00511: other glycan degradation 05322: systemic lupus erythematosus
04142: lysosome
04144: endocytosis
04540: gap junction
Downregulated
00071: fatty acid metabolism 00010: glycolysis/Gluconeogenesis
00380: tryptophan metabolism 00071: fatty acid metabolism
00620: pyruvate metabolism 00640: propanoate metabolism
00770: pantothenate and CoA biosynthesis
01040: biosynthesis of unsaturated fatty acids
03320: PPAR signaling pathway
00410: beta-Alanine metabolism
00561: glycerolipid metabolism
There were 12 highly common pathways in comparisons of PPARα-dependent studies, including 4 upregulated and 8 downregulated pathways in both liver
and small intestine of mice. The PPARα-dependent comparisons were made between PPARα null and wild type mice; By contrast, there were only 4 highly
common pathways in comparisons of PPARα-independent studies, including 1 upregulated and 3 downregulated pathways in both liver and small intestine
of mice. The comparisons were made between with normal food and with WY14643 treatment.
for up-and downregulated signiﬁcantly identiﬁed pathways
based on the permutation P-values (P ≤ 0.01). According to
thebarchartinredcolorshowingthenumberofsigniﬁcantly
upregulated pathways, there was an obviously larger change
from study 1 to study 2 (from 35 to 80 involved pathways)
t h a nf r o ms t u d y3t os t u d y4( f r o m4 5t o6 2i n v o l v e d
pathways). It suggested that the regulatory mechanism of
PPARα activation by WY14643 in mouse small intestine
would be more complicated than in mouse liver, since more
changed pathways were involved in mice intestinal PPARα
regulation.
We further compared the GSEA results in each study.
The overlapping pathways among each study from our
comparative analysis were shown in Additional File 2. We
then postulated that the pathways that appear consistently
as signiﬁcant in multiple studies are more likely to be
important in PPARα activation. For tissue eﬀect, there were
two comparisons that were of interest. Both of them are
the comparisons of PPARα-dependent regulated pathways
between in small intestine and liver of mice. The overlaps
were shown in Figure 2 and Additional File 2. Obviously, in
the ﬁrst comparison (Figure 2(a)) between study 1 and 3,
there were 16 upregulated and 9 downregulated pathways
which were PPARα-dependent in both liver and intestine.
In the second comparison (Figure 2(b))b e t w e e ns t u d y2
and 4, there were 31 upregulated and 39 downregulated
WY14643 PPARα-dependent pathways in common in both
tissues of mice, which shared larger number than the
ﬁrst comparison result. It suggests that PPARα ligand
plays an important role in directing regulation of gene
expression by PPARα. Furthermore, in order to identify the
highly common pathways appearing in both intestinal and
hepatic studies, we compared the 25 common pathways
in the ﬁrst comparison with the 70 common pathways
in the second comparison. As a result, there were 12
highly common pathways PPARα-dependent in both tissues,
including 4 upregulated and 8 downregulated pathways in
PPARα KO mice (see Table 3). The most downregulated
pathwaysweremetabolismrelatedpathway,suchasfattyacid
metabolism, tryptophan metabolism, pyruvate metabolism,
pantothenate and CoA biosynthesis, biosynthesis of unsatu-
rated fatty acids, beta-Alanine metabolism, and glycerolipid
metabolism identiﬁed in both liver and intestine [28–31].
Besides, PPAR signaling pathway was also identiﬁed as one
of the most common downregulated pathways, which is
part of endocrine system. Among the upregulated list, 3
pathways including lysosome, endocytosis and gap junction
are related to cellular processes, which may lead to an
enrichment of cholesterol in the plasma membrane [32].
The last one pathway named other glycan degradation is one
member of glycan biosynthesis and metabolism. It suggested
that the biosynthesis and metabolism of glycan may be
downregulated with regard to PPARαregulationin both liver
and intestine of mice.
In addition, there were several tissue-specially identi-
ﬁed pathways. For example, some signaling pathways such
as MAPK signaling pathway, TGF-beta signaling pathway,
VEGF signaling pathway, insulin signaling pathway, and
some disease-related pathways such as type I diabetes mel-
litus and autoimmune thyroid disease were only identiﬁed
in hepatic study. Interestingly, MAPK signaling pathway was
PPARα-dependent in liver but WY14643 PPARα-dependent
in small intestine, which was presented in brown color
in Additional File 1. The relationships between PPARα
activation and some of these identiﬁed pathways in the
tissue of liver were reported by previous studies [33–35].
By contrast, other some signaling pathways such as mTOR
signaling pathway, Notch signaling pathway, T cell receptor
signaling pathway were only identiﬁed in small intestinal
study.Moreover,therewerelotsofcancerpathwaysidentiﬁedPPAR Research 5
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Figure 1: The number of identiﬁed up-or downregulated path-
ways in four studies of PPARα-dependent side. The bar chart
showing the number of signiﬁcantly identiﬁed pathways (P ≤
0.01) in our four studies of PPARα-dependent side according
to the data of Additional File 1 which is available online at
doi:10:1155/2011/629728. X-axis represents the number of signif-
icantly identiﬁed pathways; Y-axis represents our four studies.
The studies of Intestine-CT (KO/WT) and Liver-CT (KO/WT)
are for identifying PPARα-dependent pathways; the studies of
Intestine-WY(KO/WT)andLiver-WY(KO/WT)areforidentifying
WY14643 PPARα-dependent pathways, respectively, in mice small
intestine and liver. Red color (up) is for upregulated pathways and
blue color (down) is for downregulated pathways. There were 35
and25instudyofIntestine-CT(KO/WT),thestudyinmousesmall
intestine of wild type versus PPARα-null mice treated with normal
foodinGSE5475;80and62instudyofIntestine-WY(KO/WT),the
study in mouse small intestine of wild type versus PPARα-null mice
treated with PPARα agonist WY14643 for 5 days; 45 and 29 in study
of Liver-CT (KO/WT), the study in mouse liver of wild type versus
PPARα-null mice treated with normal food; and 62 and 74 in study
of Liver-WY (KO/WT), the study in mouse liver of wild type versus
PPARα-null mice treated with the PPARα agonist WY14643 for 5
days, respectively, for up-and down-regulated pathways.
both in small intestine and in liver, including endometrial
cancer, prostate cancer, bladder cancer, and nonsmall cell
lung cancer. But there were more cancer-related pathways
identiﬁed in mice without WY14643 treatment, especially
in liver, including pancreatic cancer and small cell lung
cancer [36–38]. The activated PPARα was known as a major
regulatorofhepaticmiRNAexpressionandPPARα-nullmice
were reported to be resistant to all of the pleiotropic eﬀects
of peroxisome proliferators, including cell proliferation
and hepatocarcinogenesis [39, 40]. With regard to cancer
pathways identiﬁed in the intestine, PPARα was also thought
to play an important role in prevention of intestinal cancer
development.
3.2. Pathway Analysis of PPARα-independent or WY14643-
dependent Gene Regulation. Subsequently, we also applied
Down
Up
19 16
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9 20
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Liver-CT
(KO/WT)
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49 31 31
23 39 35
Intestine-WY
(KO/WT)
Liver-WY
(KO/WT)
(b)
Figure 2: Comparison of PPARα-dependent regulated pathways
between in small intestine and liver of mice. Venn diagram showing
the overlapping signiﬁcantly identiﬁed pathways by the comparison
of PPARα-dependent regulated pathways between in small intestine
and liver of mice. The studies of Intestine-CT (KO/WT) and Liver-
CT (KO/WT) are for identifying PPARα-dependent pathways; the
studies of Intestine-WY (KO/WT) and Liver-WY (KO/WT) are for
identifying WY14643 PPARα-dependent pathways, respectively, in
mice small intestine and liver. Pathways of P-value less than 0.01
wereconsideredtobesigniﬁcantlyregulated.Redcolorisforupreg-
ulated pathways and green color is for downregulated pathways.
In Figure 2(a), there were 16 upregulated and 9 downregulated
PPARα-dependent pathways in common; in Figure 2(b), there were
31 upregulated and 39 downregulated WY14643 PPARα-dependent
pathways in common in both tissues of mice.
the similar GSEA approach to the other 4 studies of
PPARα-independentorWY14643-dependentside.Thestud-
ies of Intestine-WT (CT/WY) and Liver-WT (CT/WY)
are for identifying WY14643-dependent pathways by the
comparison made between with and without WY14643
treatment in small intestine or liver of wide-type mice; the
studies of Intestine-KO (CT/WY) and Liver-KO (CT/WY)
are for identifying PPARα-independent pathways by the
comparison made between with and without WY14643
treatment in small intestine or liver of PPARα-null mice.
As a result, there were 86 and 50 in study of Intestine-WT
(CT/WY); 46 and 37 in study of Intestine-KO (CT/WY); 52
and 68 in study of Liver-WT (CT/WY); and 9 and 15 in
study of Liver-KO (CT/WY), respectively, for signiﬁcantly
up- and downregulated pathways (P ≤ 0.01). The details
of identiﬁed pathways in the subsequent four studies were
also shown in Additional File 1 and Figure 3.O b v i o u s l y ,
there were less signiﬁcant pathways identiﬁed in the study
of Liver-KO (CT/WY) than in other studies. It suggested that
the liver PPARα-independent pathways are more sensitive to6 PPAR Research
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T h en u m b e ro fi d e n t i ﬁ e dp a t h w a y s
Up
Down
Figure 3: The number of identiﬁed up-or downregulated pathways
in other four studies of PPARα-independent side or WY14643-
dependent side. The bar chart showing the number of signiﬁcantly
identiﬁed pathways (P ≤ 0.01) in additional four studies of
PPARα-independent side or WY14643-dependent side according
to the data of Additional File 1. X-axis represents the number of
signiﬁcantlyidentiﬁedpathways;Y-axisrepresentsourfourstudies.
The studies of Intestine-WT (CT/WY) and Liver-WT (CT/WY)
are for identifying WY14643-dependent pathways; the studies of
Intestine-KO (CT/WY) and Liver-KO (CT/WY) are for identifying
PPARα-independent pathways, respectively, in mice small intestine
and liver. Red color (up) is for upregulated pathways and blue
color (down) is for downregulated pathways. There were 86 and
50 in study of Intestine-WT (CT/WY), the study in mouse wild
type intestine of comparison between with normal food and with
the treatment of WY14643 in GSE5475; 46 and 37 in study of
Intestine-KO(CT/WY),thestudyinmousePPARα-nullintestineof
the comparison between with normal food and with the treatment
of WY14643 also in GSE5475; 52 and 68 in study of Liver-WT
(CT/WY), the study in mouse wild type liver of comparison
between with normal food and with the treatment of WY14643
in GSE8295; And 9 and 15 in study of Liver-KO (CT/WY), the
study in mouse PPARα-null liver of the comparison between with
normal food and with the treatment of WY14643 also in GSE8295,
respectively, for up-and downregulated pathways.
regulation by WY14643 while the intestine PPARα pathways
a r em o r ed e p e n d e n to nP P A R α activation by WY14643.
Further comparisons were performed to determine the
common pathways of PPARα-independent or WY14643-
dependent eﬀect based on the results of additional four
PPARα-independent or WY14643-dependent studies. The
overlaps of signiﬁcantly identiﬁed pathways by the com-
parison of PPARα-independent or WY14643-dependent
regulated pathways between in small intestine and liver of
mice were exhibited in Figure 4 and the details were shown
in Additional File 3. As a result, there were 30 upregulated
and 34 downregulated WY14643-dependent pathways in
common between study of 5 and 7 (Figure 4(a)); And
there were only 4 upregulated and 8 downregulated PPARα-
independent pathways in common between study of 6 and
Liver-WT
(CT/WY)
Intestine-WT
(CT/WY)
56
16
22 30
34 34
Down
Up
(a)
Liver-KO
(CT/WY)
Intestine-KO
(CT/WY)
42 4 5
29 8 7
Down
Up
(b)
Figure 4: Comparison of PPARα-independent or WY14643-
dependent regulated pathways between in small intestine and
liver of mice. Venn diagram showing the overlapping signiﬁcantly
identiﬁed pathways by the comparison of PPARα-independent or
WY14643-dependent regulatedpathwaysbetween insmallintestine
and liver of mice. The studies of Intestine-WT (CT/WY) and Liver-
WT (CT/WY) are for identifying WY14643-dependent pathways;
the studies of Intestine-KO (CT/WY) and Liver-KO (CT/WY)
are for identifying PPARα-independent pathways, respectively, in
mice small intestine and liver. Pathways of P value less than
0.01 were considered to be signiﬁcantly regulated. Red color is
for upregulated pathways and green color is for downregulated
pathways. In (a), there were 30 upregulated and 34 downregulated
WY14643-dependent pathways in common; in (b), there were only
4 upregulated and 8 downregulated PPARα-independent pathways
in common in both tissues of mice.
8( Figure 4(b)). Furthermore, we compared the 64 common
pathways in the ﬁrst comparison with the 12 common
pathways in the second comparison in order to identify the
highly common pathways of PPARα-independent appearing
in both intestinal and hepatic studies. Interestingly, 4 highly
common PPARα-independent pathways were identiﬁed,
including only 1 upregulated and 3 downregulated pathways
by the comparison between with normal food and with the
treatment of WY14643 (Table 3). All of the downregulated
pathways were metabolism related, including gluconeoge-
nesis, fatty acid metabolism and propanoate metabolism.
Among them, the pathway of fatty acid metabolism was
a l s oi d e n t i ﬁ e di nP P A R α-dependent studies, which had
been conﬁrmed to be related to the regulation of PPARα.
The only one upregulated pathway was systemic lupus
erythematosus (SLE), one part of human diseases, which
was reported as a heterogeneous disease involving several
immune cell types and proinﬂammatory signals and the
recent study of a novel mechanism through which PPARγ
regulated the inﬂammatory signal initiated by activation of
CD40 was importantly implicated for the understandingPPAR Research 7
of immunological mechanisms underlying SLE and the
development of new treatment strategies [41].
There were other more tissue-special pathways identi-
ﬁed in the studies of PPARα-independent or WY14643-
dependent eﬀect. Although there were less signiﬁcant path-
ways identiﬁed as PPARα-independent in study of Liver-KO
(CT/WY), the metabolism related pathway of keratan sulfate
biosynthesis, the pathway of regulation of actin cytoskele-
ton, the pathways of prostate cancer and small cell lung
cancer were not identiﬁed as hepatic PPARα-independent
but as WY14643-dependent ones in study of Intestine-WT
(CT/WY). The ﬁndings were shown in blue color in Addi-
tional File 1. The pathway of keratan sulfate biosynthesis also
named as glycosaminoglycan biosynthesis-keratan sulfate is
one part of glycan biosynthesis and metabolism. Although
there were few reports on the relationship between this
pathway and PPARs, the eﬀect of PPAR ligands modulating
glucose metabolism was reported to alter the incorporation
of metabolic precursors into proteoglycans synthesized by
human vascular smooth muscle cells [42]. The pathway of
regulation of actin cytoskeleton is cellular processes related.
A previous study indicated that stimulation of PPARα would
enhance cardiomyogenesis in ES cells using a pathway
that involves ROS and NADPH oxidase activity [43]. The
pathways of prostate cancer and small cell lung cancer are
both human diseases related. A study of the mechanism of
DEHP tumorigenesis suggested that increases in oxidative
stress induced by DEHP exposure may lead to the induction
of inﬂammation and/or the expression of protooncogenes,
resulting in a high incidence of tumorigenesis in PPARα-null
mice [44].
Finally, we compared our reanalysis results with existing
analysis previously reported. According to genome-wide
analysis of PPARα activation in murine small intestine
based on GSE5475, PPARα was reported to be involved
in the regulation of processes including immune system,
cell proliferation and diﬀerentiation, and programmed cell
death in intestine. It also remarkably indicated that almost
all increased gene sets by PPARα activation corresponded
to metabolic processes, including fatty acids catabolism,
mitochondrial oxidative metabolism, and several pathways
that feed intermediately metabolites into these processes
in small intestine of mice [14]. Based on comprehensive
analysis of PPARα-dependent regulation of hepatic lipid
metabolism by expression proﬁling of GSE8295, many Gene
Ontology classes including fatty acid beta-oxidation, acyl-
CoA metabolism, leukotriene metabolism, and peroxisome
organization and biogenesis were found to be governed by
PPARα [15]. Moreover, there were many cancer pathways
identiﬁed both in small intestine and in liver, including
endometrial cancer, prostate cancer, bladder cancer, and
nonsmall cell lung cancer according to our comparative
study of mouse hepatic and intestinal gene expression pro-
ﬁles under PPARα knockout by gene set enrichment analysis.
According to transcriptome analysis of endometrial cancer,
peroxisome proliferator-activated receptors were reported
as potential therapeutic targets in endometrial cancer [45].
The overexpression of PPARα in advanced prostate cancer
may indicate a role in tumor progression with the potential
involvement of dietary factors through fatty acid and steroid
hormone signaling pathways [46]. PPARα and PPARγ were
reported to be coexpressed, functional and show positive
interactionsintheraturinarybladderurotheliumandoxida-
tive stress may contribute to rat urothelial carcinogenesis by
dual-acting PPARα and PPARγ agonists [47]. The result of
a previous study suggested that the enhancement of PPARγ
activity with its ligands, and the suppression of PPARα with
its inhibitors, may prevent the formation of lung tumors, as
well as accelerate the therapy of lung cancer [48]. By our
further comparisons, we also provided more tissue-special
pathways PPARα-dependent or independent. We have also
identiﬁed 12 PPARα-dependent and 4 PPARα-independent
highly common in both small intestine and liver of mice.
Some of them have been approved by previous studies,
such as fatty acid metabolism of both PPARα-dependent
and independent eﬀect and PPAR signaling pathway of
PPARα-dependent eﬀe c t .W h i l ew eh a v ei d e n t i ﬁ e ds o m e
unique PPAR-dependent or independent pathways no previ-
ously identiﬁed, including the PPAR-dependent pathway of
other glycan degradation associated with glycan biosynthesis
and metabolism and the PPAR-independent pathway of
systemic lupus erythematosus related to immune system
diseases.
3.3. Tissue-Speciﬁc Genes in the Highly Common PPARα-
Dependent Pathways. Our analysis revealed that there were
12 highly common PPARα-dependent pathways identiﬁed in
both tissues, including 4 upregulated and 8 downregulated
pathways. In order to identify tissue-speciﬁc PPARα regu-
lated genes, we further analyzed the datasets and listed the
candidate genes of these highly common pathways in each
study (see in Additional File 3). Obviously, the number of
the candidate genes of each pathway in hepatic studies was
always more than the number in small intestinal studies,
which indicates that more regulated genes participate in
PPARα activation in murine liver. On the other hand, the
genes in red color in Additional File 3 were our candidate
ones of liver-speciﬁc genes in each highly common pathway,
which just appeared in hepatic studies (Study 3 and 4). The
genes of Acsl3 and Cyp4a29 were identiﬁed in the pathway of
fatty acid metabolism just in hepatic studies [49, 50]. Other
liver-speciﬁc genes in other pathways were as follows: Ccbl1,
Maob,andTph2wereidentiﬁedinthepathwayoftryptophan
metabolism; Pank2 and Pank4 were identiﬁed in pathway of
pantothenate and CoA biosynthesis; Yod1 was in pathway of
biosynthesis of unsaturated fatty acids; Cpt1c and Cyp4a29
were in PPAR signaling pathway; Cndp1 was in pathway of
beta-Alanine metabolism; Agpat2, Agpat4, Dgki, Dgkb, and
Dgkh were in the pathway of glycerolipid metabolism; Aga
and D230014K01Rik were in the pathway of other glycan
degradation; N p c 1 ,A r s b ,C t s o ,A g a ,G g a 3 ,and Ap4e1 were in
the pathway of lysosome; Adcy5, Tubb1, Adcy1, Drd1a, Grm5,
and Gucy1a2 were in the pathway of gap junction. Moreover,
the pathway of endocytosis was a unique one, in which many
geneswereidentiﬁed.Forexample,Psd2, Smurf1 andArfgap3
werejustidentiﬁedinstudy3and4.Wesuggestthatallofthe
identiﬁed genes could be seen as our candidate liver-speciﬁc
genes, but needed of further study.8 PPAR Research
4. Conclusions
Our study strongly indicates that the consolidation of the
twodiﬀerenttissue(liverandsmallintestine)expressiondata
sets can increase data quality and can lead to biologically
more meaningful results. We have performed 8 PPARα
or WY14643-dependent and independent studies by using
GSEA on microarray datasets and making comparisons. In
intestinal studies, we have identiﬁed 35 and 25 PPARα-
dependent, 80 and 62 WY14643 PPARα-dependent, 86 and
50 WY14643-dependent and 46 and 37 PPARα-independent
up-and downregulated pathways. In hepatic studies, we have
identiﬁed 45 and 29 PPARα-dependent, 62 and 74 WY14643
PPARα-dependent, 52 and 68 WY14643-dependent and 9
and 15 PPARα-independent up-and downregulated path-
ways. We suggested that the regulatory mechanism of PPARα
activation by WY14643 in mouse small intestine would be
more complicated than in mouse liver since more changed
pathways were involved in mice intestinal PPARα regulation.
Moreover, there were several cancer-related pathways such
as pancreatic cancer and small cell lung cancer identiﬁed in
mice without WY14643 treatment especially in liver, which
indicated that PPARα was thought to play an important
role in prevention of cancer development. Finally, we found
12 PPARα-dependent pathways and 4 PPARα-dependent
pathways identiﬁed highly common in both tissues of mice.
Most of them were metabolism related, such as fatty acid
metabolism, tryptophan metabolism, pyruvate metabolism
with regard to PPARα regulation and gluconeogenesis, and
propanoate metabolism independent of PPARα regulation.
Furthermore, some pathways such as keratan sulfate biosyn-
thesis, the pathway of regulation of actin cytoskeleton, the
pathways associated with prostate cancer and small cell lung
cancer were not identiﬁed as hepatic PPARα-independent
but as WY14643-dependent ones in intestinal study. We have
identiﬁed some unique PPAR-dependent or independent
pathways no previously identiﬁed, including other glycan
degradation and systemic lupus erythematosus. We also
provided some novel hepatic tissue-speciﬁc marker genes.
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